AU6460200A - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
AU6460200A
AU6460200A AU64602/00A AU6460200A AU6460200A AU 6460200 A AU6460200 A AU 6460200A AU 64602/00 A AU64602/00 A AU 64602/00A AU 6460200 A AU6460200 A AU 6460200A AU 6460200 A AU6460200 A AU 6460200A
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64602/00A
Inventor
John Dixon
Philip Holt
Francis Ince
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Publication of AU6460200A publication Critical patent/AU6460200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
AU64602/00A 1999-08-18 2000-08-14 Pharmaceutical compositions Abandoned AU6460200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9902937A SE9902937D0 (en) 1999-08-18 1999-08-18 Pharmaceutical compositions
SE9902937 1999-08-18
PCT/GB2000/003114 WO2001011933A2 (en) 1999-08-18 2000-08-14 Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a pde4 inhibitor

Publications (1)

Publication Number Publication Date
AU6460200A true AU6460200A (en) 2001-03-13

Family

ID=20416695

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64602/00A Abandoned AU6460200A (en) 1999-08-18 2000-08-14 Pharmaceutical compositions

Country Status (4)

Country Link
AR (1) AR025341A1 (en)
AU (1) AU6460200A (en)
SE (1) SE9902937D0 (en)
WO (1) WO2001011933A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029984A1 (en) * 2000-07-27 2003-07-23 Smithkline Beecham Corp METHOD FOR REDUCING ASSOCIATED EXCERBATIONS COPD AMBITO
CA2543858C (en) 2003-11-21 2014-04-15 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
EP2255189B8 (en) * 2008-02-07 2015-05-06 Michael M. Grunstein Compositions and methods which modulate g-protein signaling for the treatment of asthma
US8569229B2 (en) 2008-02-07 2013-10-29 The Children's Hospital Of Philadelphia Compositions and methods which modulate G-protein signaling for the treatment of inflammatory disorders such as asthma and allergic conjunctivitis
WO2009154557A1 (en) 2008-06-18 2009-12-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211172D0 (en) * 1992-05-27 1992-07-08 Fisons Plc Compounds

Also Published As

Publication number Publication date
WO2001011933A2 (en) 2001-02-22
AR025341A1 (en) 2002-11-20
SE9902937D0 (en) 1999-08-18
WO2001011933A3 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
AU781269C (en) Pharmaceutical compositions
AU3192700A (en) Medicinal compositions
HUP0202513A2 (en) Betha-carboline pharmaceutical compositions
AU2001250420A1 (en) Pharmaceutical compositions
AU1071301A (en) Pharmaceutical compounds
GB0028088D0 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
AU3556400A (en) Pharmaceutical compositions
AU2005300A (en) Medicinal compositions
GB9923436D0 (en) Pharmaceutical compositions
AU1887401A (en) Medicinal composition
AU4328800A (en) Pharmaceutical formulation
AU1735001A (en) Cyclodextrin-containing pharmaceutical composition
AU6715600A (en) Pharmaceutical formulations
GB9904163D0 (en) Pharmaceutical compositions
AU4304400A (en) Novel pharmaceutical compositions comprising 2-isoxazole-8-aminotetralin derivatives
AU6460400A (en) Pharmaceutical compositions
AU5460800A (en) Pharmaceutical transdermal compositions
AU2001273919A1 (en) Pharmaceutical compositions
GB9911017D0 (en) Pharmaceutical compositions
AU2681500A (en) Rapidly-soluble compositions
AU4977300A (en) Pharmaceutical formulations
AU6460200A (en) Pharmaceutical compositions
AU1385801A (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase